Press Releases
Jun. 26, 2018 Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&A
RICHMOND, British Columbia & GUILFORD, Conn–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it… Read more »
Jun. 12, 2018 Bioasis Further Strengthens Scientific Advisory Board with Addition of Dr. Mario Saltarelli, Dr. Jack Hoppin and Dr. Sue O’Connor
Mario Saltarelli, M.D., Ph.D., Senior Vice President, Early Development and Neurology, Vertex Jack Hoppin, Ph.D., Co-Founder & Chief Executive Officer, Invicro Sue O’Connor, B.Sc. (Hons), Ph.D ., Vice President, Neuroscience Research, Bionomics
May. 30, 2018 Bioasis Announces Publication of Independent Validation of the Company’s xB3 ™ Platform Technology
Research Conducted by MedImmune Shows the xB 3 Platform Efficiently Delivers Antibodies Across the BBB at Therapeutic Doses xB 3 Demonstrated Sustained Systemic PK Properties of the MedImmune Antibody Constructs and Demonstrated a Strong PK/PD Dose Dependent Relationship in a Neuropathic Pain Pre-Clinical Model The Research was Published in the Journal of Cerebral Blood Flow and Metabolism 1
May. 25, 2018 Bioasis to Present at the 25th Annual BIO International Convention
Bioasis will present at the 25th Annual BIO International Convention, to be held June 4-7, 2018 at the Boston Convention & Exhibition Center.
May. 24, 2018 Bioasis Announces Closing of Second Tranche of Previously Disclosed Private Placement
This News Release is Not for Distribution to U.S. Newswire Services or Dissemination in the United States
May. 21, 2018 Bioasis and WuXi Biologics Announce Initial Strategic Collaboration for the Development and Manufacturing of xB3-001, the Company’s Lead Investigational Candidate to Treat Brain Cancer
Bioasis will draw on WuXi Biologics’ expertise in developing complex biologic molecules for production of xB 3 -001 to support analytical development, formulation and IND-enabling in vivo studies
May. 17, 2018 Bioasis Announces Closing of First Tranche of Previously Disclosed Private Placement
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
May. 14, 2018 Bioasis Announces Private Placement and Intention to Pursue NASDAQ Listing
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
Mar. 26, 2018 Bioasis Announces Key Strategic Appointment to its Senior Leadership Team with Addition of Caroline Hill, Ph.D., Leading Research & Development Operations
VANCOUVER, British Columbia & GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company with a proprietary blood-brain barrier platform delivery technology focused on development of therapeutics for the treatment of brain cancers and neurodegenerative diseases, today announced a key strategic appointment to its senior leadership team with the addition of Caroline Hill, Ph.D.,… Read more »
Mar. 21, 2018 Bioasis Appoints Deborah Rathjen, B.Sc. (Hons), Ph.D., MAICD, FTSE as Chair of the Board of Directors
Dr. Rathjen is the Chief Executive Officer and Managing Director of Bionomics in Adelaide, Australia; Dr. Rathjen joined the Bioasis Board in September 2017